Financial Advisory Service Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,971 shares of the company’s stock after purchasing an additional 131 shares during the period. Financial Advisory Service Inc.’s holdings in Johnson & Johnson were worth $1,981,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. State Street Corp boosted its holdings in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock valued at $1,521,258,000 after buying an additional 405,517 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 1.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock valued at $1,388,775,000 after buying an additional 201,703 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Johnson & Johnson by 3.4% in the 1st quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock valued at $1,188,684,000 after buying an additional 310,831 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Johnson & Johnson by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock valued at $990,041,000 after buying an additional 42,144 shares in the last quarter. 65.93% of the stock is currently owned by institutional investors.

Johnson & Johnson (NYSE JNJ) opened at $138.00 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $373,080.00, a PE ratio of 19.54, a PEG ratio of 2.83 and a beta of 0.82. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.68 EPS. analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.43%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-holdings-raised-by-financial-advisory-service-inc/1710967.html.

A number of analysts recently weighed in on JNJ shares. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Atlantic Securities cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a research note on Friday, July 21st. Citigroup Inc. started coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price target for the company. Finally, Goldman Sachs Group, Inc. (The) cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price target for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $143.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.